Infectious Diseases Working Party (IDWP)
Cellular Therapy & Immunobiology Working Party (CTIWP)
COVID-19
Study type:
Study number:
84140146
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Short title:
Primary objective:
• To evaluate the current practice (until February/March 2020) and change of practice in EBMT centers during the COVID-19 pandemic (since March 2020) with respect to cryopreservation of allogeneic (related and unrelated) HPC products.
• To assess possible changes in donor selection (e.g. switch to haplo-related instead of unrelated donor, identification of a backup donor, etc.) during the COVID-19 pandemic.
• To identify reorganization/reallocation of resource – including human resource – necessary to transit from prior to current organization
• To assess possible changes in donor selection (e.g. switch to haplo-related instead of unrelated donor, identification of a backup donor, etc.) during the COVID-19 pandemic.
• To identify reorganization/reallocation of resource – including human resource – necessary to transit from prior to current organization
Key inclusion criteria:
Country:
Principal investigator:
Nina Worrel
EBMT Study coordinator:
Inge Verheggen
Study coordinator email:
idwp.ebmt@lumc.nl